atai Life Sciences (ATAI) — atai Life Sciences said management would appear at several investor conferences in September 2025.
The circuit gave the company a platform to make its case to institutional investors as it advanced its planned strategic combination with Beckley Psytech, which it had guided toward a shareholder-approval stage in Q4 2025 following July's positive BPL-003 Phase 2b topline. It is an investor-relations event rather than a clinical catalyst.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.